Compare MYSZ & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | TCRT |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.4M |
| IPO Year | 2017 | 2025 |
| Metric | MYSZ | TCRT |
|---|---|---|
| Price | $1.56 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 708.3K | 410.5K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | 24.66 |
| EPS | N/A | ★ N/A |
| Revenue | $142,000.00 | ★ $15,900,000.00 |
| Revenue This Year | $38.86 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.33 | $0.78 |
| 52 Week High | $4.28 | $4.57 |
| Indicator | MYSZ | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 25.72 |
| Support Level | $0.47 | N/A |
| Resistance Level | $2.60 | $2.09 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 5.52 | 0.18 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.